Date | Time | Source | Announcement |
---|---|---|---|
28 Apr 2008 | 07:00 AM | Net Asset Value(s) | |
13 Mar 2008 | 10:48 AM | Holding(s) in Company | |
04 Feb 2008 | 07:00 AM | Net Asset Value(s) | |
21 Jan 2008 | 05:50 PM | Holding(s) in Company | |
22 Nov 2007 | 07:02 AM | Director/PDMR Shareholding | |
22 Nov 2007 | 07:01 AM | Change of Adviser | |
22 Oct 2007 | 07:01 AM | Net Asset Value(s) | |
28 Sep 2007 | 10:27 AM | Interim Results | |
19 Sep 2007 | 10:50 AM | Holding(s) in Company | |
16 Aug 2007 | 07:00 AM | Rule 26 Notification | |
03 Aug 2007 | 01:58 PM | Net Asset Value(s) | |
01 Aug 2007 | 03:32 PM | Result of AGM | |
11 Jul 2007 | 08:16 AM | Update on development | |
29 Jun 2007 | 07:00 AM | Final Results | |
25 Jun 2007 | 11:36 AM | Acquisition | |
18 Jun 2007 | 07:00 AM | Acquisition | |
14 Jun 2007 | 07:00 AM | Acquisition | |
04 Jun 2007 | 07:01 AM | Acquisition | |
22 May 2007 | 03:27 PM | Holding(s) in Company | |
21 May 2007 | 03:22 PM | Director/PDMR Shareholding | |
30 Apr 2007 | 07:01 AM | Acquisition | |
23 Apr 2007 | 07:00 AM | Net Asset Value(s) | |
09 Feb 2007 | 05:59 PM | Director/PDMR Shareholding | |
29 Jan 2007 | 02:36 PM | Director/PDMR Shareholding | |
22 Jan 2007 | 07:01 AM | Appointment of Director | |
22 Jan 2007 | 07:01 AM | Net Asset Value(s) | |
19 Dec 2006 | 03:48 PM | Voting rights and capital | |
15 Dec 2006 | 04:25 PM | Director/PDMR Shareholding | |
15 Dec 2006 | 07:00 AM | Admission to AIM |
Fusion Antibodies is a biotechnology company that specializes in antibody development services for the healthcare industry. The company was founded in 2001 as a spin-out from Queen's University Belfast and is headquartered in Belfast, Northern Ireland. Fusion Antibodies offers antibody discovery, engineering, supply, and cell line development. It has developed proprietary technology platforms such as CDRx® for antibody humanization, RAMP® for affinity maturation, and ADD™ for developability optimization.
FAB share price launched at 165p in 2017.